Recombinant PRG4 Composition to Block NGF Pain Sensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological therapies for pain management, such as NSAIDs and opioids, have undesirable side effects and limited efficacy, particularly for chronic pain, and there is a need for safer and more effective treatments.
Innovation Solution
Administration of a pharmaceutically effective amount of recombinant human PRG4 (rhPRG4) or its fragments to inhibit TNF)-α simulated nerve growth factor (NGF), transient receptor potential ankyrin 1 (TrpA1) expression, and nerve growth factor (NGF)/tropomyosin receptor kinase A (TrkA) binding, thereby reducing acute and chronic pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If NSAIDs are used for pain relief, then pain is reduced, but gastric ulcers and kidney damage occur
Solution Approach 1:
The patent uses intra-articular injection of viscosupplements (hyaluronic acid) and PRG4 as intermediary substances that directly target the joint space to provide pain relief and protective effects, avoiding systemic circulation and thereby preventing gastric and renal side effects associated with oral NSAID administration
Solution Approach 2:
The patent extracts and utilizes the protective and lubricating functions of PRG4, a naturally occurring joint protein, to provide localized therapy that addresses pain and tissue protection without the harmful systemic effects of conventional pharmacological agents
2Object-affected harmful factors
If opioids are used for pain management, then pain relief is achieved, but risk of abuse and tolerance increases
Solution Approach 1:
The patent employs PRG4 as a mediator that acts on joint tissues through physiological lubrication and protection mechanisms, providing pain relief through non-opioid pathways that do not carry the risk of abuse or tolerance development
Solution Approach 2:
The patent leverages the body's own PRG4 protein, which naturally protects joint tissues, to provide therapeutic effects that work through endogenous protective mechanisms rather than exogenous substances that create dependency
3Object-affected harmful factors
If intra-articular glucocorticoids are administered, then acute pain is reduced, but duration of effect is limited to a few days
Solution Approach 1:
The patent administers viscosupplements and PRG4 that provide continuous therapeutic action by maintaining viscosupplementation in the joint space, offering prolonged pain relief and protective effects that extend beyond the brief duration of glucocorticoid action
Solution Approach 2:
The patent uses PRG4 as a sustained-acting intermediary that continuously protects joint tissues through lubrication and anti-inflammatory mechanisms, providing longer-lasting relief compared to short-acting glucocorticoids
Data Source
AI summary
The present disclosure relates to administration of pharmaceutically acceptable composition as a means to reduce acute and chronic pain and treat other conditions. Pharmaceutical acceptable composition comprising a pharmaceutically effective amount of a full length recombinant human PRG4 (rhPRG4) or a fragment thereof and a pharmaceutically acceptable carrier or diluent.